ES2149361T3 - Vacuna viva modificada contra el brsv, mejorada. - Google Patents

Vacuna viva modificada contra el brsv, mejorada.

Info

Publication number
ES2149361T3
ES2149361T3 ES95918442T ES95918442T ES2149361T3 ES 2149361 T3 ES2149361 T3 ES 2149361T3 ES 95918442 T ES95918442 T ES 95918442T ES 95918442 T ES95918442 T ES 95918442T ES 2149361 T3 ES2149361 T3 ES 2149361T3
Authority
ES
Spain
Prior art keywords
brsv
adjuvant
improved
immunity
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95918442T
Other languages
English (en)
Inventor
Hsien-Jue Chu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2149361T3 publication Critical patent/ES2149361T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION PROPORCIONA UNA COMPOSICION DE VACUNA BRSV MEJORADA, QUE PROPORCIONA VENTAJOSAMENTE INMUNIDAD CONTRA LA INFECCION DESPUES DE UNA SOLA ADMINISTRACION. LA COMPOSICION INCLUYE UN VIRUS BRS VIVO ALTERADO Y UN ADYUVANTE, QUE PROPORCIONAN CONJUNTAMENTE INMUNIDAD FRENTE A LA INFECCION POR BRSV DESPUES DE UNA SOLA ADMINISTRACION, CONSIGUEN UNA RESPUESTA INMUNE ESPECIFICA A BRSV E INCLUYEN INMUNIDAD MEDIADA CELULARMENTE E INMUNIDAD LOCAL ( SECRECION IGA). EN LA VERSION PREFERIDA, EL VIRUS BRS ES DE LA VARIEDAD 375, Y EL ADYUVANTE INCLUYE UN HIDROCARBONO DE TURPINA INSATURADO, PREFERIBLEMENTE SECUALENO O SECUALANO, Y UN COPOLIMERO EN BLOQUE DE POLIOXIPROPILENO-POLIXIETILENO, MAS ESPECIFICAMENTE UNO EN EL QUE EL COPOLIMERO TENGA UN COMPONENTE POLIOXIPROPILENO (POP) CON UN PESO MOLECULAR MEDIO COMPRENDIDO ENTRE 3250 Y 4000 , SUPONIENDO EL COMPONENTE DE POLIOXIETILENO (POE) ENTRE UN 10-20% DE LA MOLECULA TOTAL. EL ADYUVANTE PUEDE INCLUIR OPCIONALMENTE UN SURFACTANTE, PREFERIBLEMENTE UN MONOOLEATO DE POLIOXIETILENESORBITANO.
ES95918442T 1994-05-10 1995-05-08 Vacuna viva modificada contra el brsv, mejorada. Expired - Lifetime ES2149361T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24037394A 1994-05-10 1994-05-10

Publications (1)

Publication Number Publication Date
ES2149361T3 true ES2149361T3 (es) 2000-11-01

Family

ID=22906268

Family Applications (3)

Application Number Title Priority Date Filing Date
ES95918442T Expired - Lifetime ES2149361T3 (es) 1994-05-10 1995-05-08 Vacuna viva modificada contra el brsv, mejorada.
ES07008378T Expired - Lifetime ES2429401T3 (es) 1994-05-10 1995-05-08 Vacuna viva modificada contra el BRSV, mejorada
ES99115633T Expired - Lifetime ES2287997T3 (es) 1994-05-10 1995-05-08 Vacuna viva modificada contra el brsv mejorada.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES07008378T Expired - Lifetime ES2429401T3 (es) 1994-05-10 1995-05-08 Vacuna viva modificada contra el BRSV, mejorada
ES99115633T Expired - Lifetime ES2287997T3 (es) 1994-05-10 1995-05-08 Vacuna viva modificada contra el brsv mejorada.

Country Status (19)

Country Link
US (2) US5733555A (es)
EP (4) EP0968722B1 (es)
JP (3) JP3993230B2 (es)
KR (1) KR100374434B1 (es)
CN (1) CN1268393C (es)
AT (2) ATE195255T1 (es)
AU (1) AU711350B2 (es)
BR (1) BR9507717A (es)
CA (1) CA2189979C (es)
DE (2) DE69535520T2 (es)
DK (2) DK0968722T3 (es)
ES (3) ES2149361T3 (es)
GR (1) GR3034402T3 (es)
MY (1) MY111829A (es)
NZ (1) NZ285324A (es)
PT (3) PT759780E (es)
SI (2) SI0968722T1 (es)
WO (1) WO1995030437A1 (es)
ZA (1) ZA953703B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
ATE220327T1 (de) * 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
CA2136677A1 (en) * 1993-12-29 1995-06-30 Intervet, Inc. Method of intranasally administering to bovines a trivalent vaccine containing modified live ibrv, pl3v and brsv
ES2218543T3 (es) * 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
WO1995030437A1 (en) * 1994-05-10 1995-11-16 American Home Products Corporation Improved modified live brsv vaccine
NZ285664A (en) * 1994-05-18 1998-07-28 Inhale Therapeutic Syst Dry powder interferon composition adapted for pulmonary delivery
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
JP3939752B2 (ja) * 1994-10-05 2007-07-04 バンダービルト ユニバーシティー パラミクソウイルスワクチン用アジュバントとしてのインターロイキン−１２
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6908618B2 (en) 1997-11-10 2005-06-21 University Of Maryland Production of novel bovine respiratory syncytial viruses from cDNAs
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
TW440845B (en) 1999-08-11 2001-06-16 Ibm Method and system for programming FPGAs on PC-cards without additional hardware
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
AU2001280934A1 (en) * 2000-07-28 2002-02-13 Alliance Pharmaceutical Corp. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
AU2002342568B2 (en) 2001-05-10 2007-11-01 Wyeth Composition and method for increasing cell density in cell cultures infected with lentivirus
PT1474067E (pt) 2001-07-02 2008-11-14 Pfizer Prod Inc Vacinação numa dose com mycoplasma hyopneumoniae
AU2002365244B2 (en) * 2001-07-27 2007-12-06 Zoetis Services Llc West nile vaccine
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
NZ538394A (en) * 2002-08-26 2008-06-30 Pfizer Prod Inc Vaccine for respiratory and reproductive system infections in cattles
CA2551026A1 (en) * 2003-12-23 2005-07-14 Schering Corporation Methods for producing a549 cell lines stable in serum-free medium suspension culture
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8097288B1 (en) * 2008-04-16 2012-01-17 Pom Wonderful, Llc Composition and method for providing nutritional immunology for production animals
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
KR20080044258A (ko) * 2005-08-04 2008-05-20 와이어쓰 수의용 백신을 위한 안정화제
EP2275132B1 (en) 2005-12-29 2021-03-03 Boehringer Ingelheim Animal Health USA Inc. Multivalent PCV2 immunogenic compositions and methods of producing them
MX338626B (es) 2005-12-29 2016-04-26 Boehringer Ingelheim Vetmed Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
EP1911836A1 (en) * 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Medium supplement for virus production
EP2859900A1 (en) * 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
BRPI0721083A2 (pt) * 2006-12-15 2014-02-25 Boehringer Ingelheim Vetmed Tratamento de porcos com antígeno de pcv2
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
JP5613061B2 (ja) * 2008-01-23 2014-10-22 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Ｐｃｖ２マイコプラズマ・ハイオニューモニエ免疫原性組成物および前記組成物の製造方法
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
AR084358A1 (es) 2010-12-27 2013-05-08 Lilly Co Eli Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc))
EP2658570B1 (en) * 2010-12-27 2018-11-28 Elanco US Inc. Bovine viral diarrhea virus type 1b vaccine compositions and methods
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
ES2882374T3 (es) 2013-05-08 2021-12-01 Pharmgate Biologics Inc Vacuna para PCV2 y micoplasma
KR102319843B1 (ko) 2013-09-25 2021-10-29 조에티스 서비시즈 엘엘씨 Pcv2b 분지형 백신 조성물 및 사용 방법
US9505808B2 (en) 2013-10-02 2016-11-29 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
JP7783047B2 (ja) * 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
CA3157405A1 (en) * 2019-11-18 2021-05-27 Donald D. EVANS II Lyophilized cake in straight-walled vial
EP4093415A1 (en) 2020-01-24 2022-11-30 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized na
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8301996A (nl) * 1983-06-06 1985-01-02 Duphar Int Res Werkwijze ter bereiding van geadjuveerde levende vaccins en aldus verkregen geadjuveerde levende vaccins.
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
WO1995030437A1 (en) * 1994-05-10 1995-11-16 American Home Products Corporation Improved modified live brsv vaccine

Also Published As

Publication number Publication date
US5733555A (en) 1998-03-31
ES2287997T3 (es) 2007-12-16
PT759780E (pt) 2001-01-31
US5958423A (en) 1999-09-28
KR970703166A (ko) 1997-07-03
EP0759780B1 (en) 2000-08-09
EP1844791A1 (en) 2007-10-17
ES2429401T3 (es) 2013-11-14
DK0759780T3 (da) 2000-11-13
EP1820512A1 (en) 2007-08-22
EP0968722A1 (en) 2000-01-05
JPH10500113A (ja) 1998-01-06
NZ285324A (en) 1998-08-26
SI0759780T1 (en) 2000-12-31
ATE195255T1 (de) 2000-08-15
CA2189979C (en) 2011-04-19
CN1268393C (zh) 2006-08-09
JP2011246489A (ja) 2011-12-08
HK1024412A1 (en) 2000-10-13
GR3034402T3 (en) 2000-12-29
DE69518316D1 (de) 2000-09-14
KR100374434B1 (ko) 2003-06-09
JP2007137905A (ja) 2007-06-07
SI0968722T1 (sl) 2007-10-31
AU711350B2 (en) 1999-10-14
DE69518316T2 (de) 2001-03-29
PT968722E (pt) 2007-09-06
CA2189979A1 (en) 1995-11-16
DK0968722T3 (da) 2007-09-24
EP1820512B1 (en) 2013-07-03
EP0968722B1 (en) 2007-06-20
BR9507717A (pt) 1997-09-23
AU2438795A (en) 1995-11-29
JP3993230B2 (ja) 2007-10-17
DE69535520T2 (de) 2008-02-07
PT1820512E (pt) 2013-10-09
DE69535520D1 (de) 2007-08-02
EP0759780A1 (en) 1997-03-05
MY111829A (en) 2001-01-31
ZA953703B (en) 1996-01-10
ATE365049T1 (de) 2007-07-15
WO1995030437A1 (en) 1995-11-16
CN1152878A (zh) 1997-06-25

Similar Documents

Publication Publication Date Title
DE69518316D1 (de) Modifizierter,verbesserter,lebender brsv impfstoff
ME00569A (en) Improved mycoplasma hyopneumoniae bacterin vaccine
ME00570A (en) Improved mycoplasma hyopneumoniae bacterin vaccine
DE122010000042I1 (de) Solubilisierung von capsulären Polysacchariden
WO2003055513A3 (en) Bacillus subtilis spores to stimulate the immune responses
BRPI9911870B8 (pt) vacina de parvovírus e circovírus de suíno
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
ES2192582T3 (es) Composicion de vaccineo, conteniendo quitina, parcialmente deacetilado.
WO2002009746A3 (en) Vaccines comprising outer membrane vesciles from gram negative bacteria
HUP0100058A1 (hu) LTB Adjuvánst tartalmazó vakcinák
DK0654086T3 (da) Vacciner mod Aujeszky's sygdom og andre dyresygdomme indeholdende mutanter af pseudo-rabies-virus
NO20023935L (no) Ny, ikke-antigen, mukosal adjuvansformulering som modulerer effektene av substanser inkludert vaksineantigener, i kontakt medmukosale kroppsoverflater
ATE182270T1 (de) Mukosale verabreichung von pneumokokken-antigenen
DE60031243D1 (de) Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
NZ330913A (en) Antigens for preventing and reducing parasite infection and disease
MX9605503A (es) Vacuna mejorada de virus sincitial respiratorio debovino (brsv) vivo, modificado.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 759780

Country of ref document: ES